longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

ADARx Pharmaceuticals

ADRX

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current Valuation

-24.37xP/E
$20.09Stock price
$-0.82Earnings per share
-24.37xP/E
Stock price$20.09Earnings per share$-0.82

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GILDUSGilead Sciences
-58.25x148.77%$188.73B
MRNAUSModerna
-25.00x15.47%$78.76B
CSLLYUSCSL Limited
-23.77x--$61.30B
NTRAUSNatera
-308.58x8.22%$59.35B
RVMDUSRevolution Medicines
-24.45x63.01%$43.24B
ROIVUSRoivant Sciences
-100.32x146.49%$26.71B
INSMUSInsmed
-29.36x74.61%$25.70B
BNTXUSBioNTech SE
-12.71x17.57%$24.89B
BBIOUSBridgebio Pharma
-18.82x28.48%$13.02B
SMMTUSSummit Therapeutics
-14.43x19.83%$12.35B
MDGLUSMadrigal Pharma
-36.75x51.06%$11.95B
TWSTUSTwist Bioscience
-86.48x20.00%$11.82B
KYMRUSKymera Therapeutics
-31.08x4.94%$9.31B
ARWRUSArrowHead Pharma
-28.90x36,308.30%$9.25B
CYTKUSCytokinetics
-10.29x6.37%$9.20B
IBRXUSImmunityBio
-9.10x152.63%$9.03B
PCVXUSVaxcyte
-8.15x48.80%$8.67B
ABVXUSAbivax SA
-18.13x22.49%$8.44B
PRAXUSPraxis Precision Medicines
-23.52x3.05%$7.98B
IONSUSIonis Pharma
-13.40x50.60%$7.57B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.